Q-omics provides the consensus-scored ACTBP7 profile across patient tissues and cancer cell-line models. ACTBP7 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ACTBP7 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, ACTBP7 RNA expression shows 14,370 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, LUAD, and TGCT as cancer lineages where ACTBP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTBP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTBP7 survival associations across molecular data types. ACTBP7 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTBP7 RNA expression–survival associations across cancer types. High ACTBP7 expression shows unfavorable associations in MESO, OV, UVM, PAAD and ACC, but favorable associations in CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ACTBP7 RNA expression.
This table summarizes ACTBP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ACTBP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTBP7 shows lower tumor expression in KICH and higher tumor expression in LUAD, COAD, HNSC, BRCA and THCA. The LUAD box plot shows higher ACTBP7 RNA expression in tumor versus normal tissue (log2 FC = +0.358, t-test p < 0.001).
This table shows molecular features associated with ACTBP7 in patient tissues and cancer cell lines. In patient samples, ACTBP7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
